Our research results showed an increasing trend in HIF-PHIs-related embolic and thrombotic events reports since the drug’s market launch, reaching its peak in 2021, followed by a gradual decline.
← all excerpts
HIF-PHIs associated with embolic and thrombotic events: a real-world pharmacovigilance study based on the Japan Adverse Drug Event Report database.
1
—
—